Exposure to dolutegravir in pregnant women living with HIV in Central and Eastern Europe and neighboring countries - data from the ECEE Network Group

Basit Öğe Kaydı
dc.contributor.authorGokengin D.
dc.contributor.authorAho I.
dc.contributor.authorYildirim F.S.
dc.contributor.authorBukovinova P.
dc.contributor.authorSiwak E.
dc.contributor.authorPapadopoulos A.
dc.contributor.authorSedlacek D.
dc.contributor.authorKowalska J.
dc.date.accessioned2019-10-27T08:01:31Z
dc.date.available2019-10-27T08:01:31Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives: The purpose of this study was to investigate dolutegravir (DTG) use among women and exposure to DTG during pregnancy in real world in Central and Eastern Europe and neighboring countries. Material and methods: Centres from 20 countries included in the Euroguidelines in Central and Eastern Europe (ECEE) Network and Finland were asked to complete an on-line questionnaire. Results: Seven centres from Czech Republic, Finland, Greece, Poland, Slovakia, and Turkey provided detailed information. DTG exposure was reported in 415 women, of which 26 were during pregnancy. Of those, 22 were on DTG at the time of conception and 4 had started DTG during pregnancy. Few women had conventional risk factors. The data on folic acid usage was unknown for eight women; 14 were using and four were not using folic acid. Four pregnancies were ongoing at the time of the study and of those with an outcome, 77.3% resulted with term, 13.6% preterm delivery, 4.5% spontaneous and 4.5% medical abortion. Conclusions: The DTG signal report indicates the importance of safety research for drug use in pregnancy and highlights the urgent need for systematic surveillance of pregnancy outcomes and neonatal surveillance. Countries with low- or moderate HIV prevalence should be included in studies reviewing pregnancy outcomes and in any surveillance system to ensure the accuracy of drug safety revision. © 2019 Via Medica.en_US
dc.identifier.doi10.5603/GP.2019.0070en_US
dc.identifier.endpage415en_US
dc.identifier.issn0017-0011
dc.identifier.issue7en_US
dc.identifier.pmid31392711en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage411en_US
dc.identifier.urihttps://doi.org/10.5603/GP.2019.0070
dc.identifier.urihttps://hdl.handle.net/11454/25012
dc.identifier.volume90en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherVia Medicaen_US
dc.relation.ispartofGinekologia Polskaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCentral and Eastern Europeen_US
dc.subjectDolutegraviren_US
dc.subjectHIV infectionen_US
dc.subjectPregnancyen_US
dc.titleExposure to dolutegravir in pregnant women living with HIV in Central and Eastern Europe and neighboring countries - data from the ECEE Network Groupen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu